We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Good Start Genetics, Roche Announces Marketing Agreement
News

Good Start Genetics, Roche Announces Marketing Agreement

Good Start Genetics, Roche Announces Marketing Agreement
News

Good Start Genetics, Roche Announces Marketing Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Good Start Genetics, Roche Announces Marketing Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Good Start Genetics has announced that it has entered into a collaborative agreement with global healthcare leader Roche to sell Good Start’s carrier screening service for inherited genetic disorders. Under the agreement, Roche Diagnostics will offer Good Start Genetics’ GeneVuTM carrier screening test service in conjunction with its HarmonyTM non-invasive prenatal test (NIPT) service to obstetricians and general practitioners caring for pregnant women in the United States.

"We are excited to announce our collaboration with Roche Diagnostics to address the significant market need for prenatal carrier screening utilizing our proprietary next generation sequencing technology platform," said Jeffrey Luber, President and CEO of Good Start Genetics. "It is an honor to team up with a world-class organization like Roche as we address a significant unmet need. Offering GeneVu, our comprehensive and highly accurate carrier screening test service for inherited genetic disorders, with Roche’s Harmony NIPT service, which assesses the risk of fetal trisomy 21, 18, 13, and sex chromosome aneuploidy, provides the 20,000+ OBGYNs in the United States with two best-in-class solutions for their expectant moms.”

As the nation's leading medical organization for women's health, the American College of Obstetricians and Gynecologists (ACOG) recommends that the more than 60 million women of reproductive age in the U.S. be offered genetic testing for cystic fibrosis (CF), while the American College of Medical Genetics and Genomics (ACMG) recommends screening for both CF and spinal muscular atrophy. The GeneVu test service offers screening for these inherited genetic conditions and others.

“The agreement with Good Start Genetics will enable Roche to offer a broader range of screening services to healthcare professionals who provide care for pregnant women and for parents involved in planning a family,” said Whitney Green, Senior Vice President, Commercial Operations for Roche Diagnostics. “Good Start’s GeneVu service is an innovative test that will complement our Harmony prenatal test service to allow prospective parents to confidently assess the risk of various genetic conditions in themselves and in the child.”

Source: Story from Good Start Genetics. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks' style and length guidelines.

Advertisement